Discovery of Highly Potent and Selective Biphenylacylsulfonamide-Based β3-Adrenergic Receptor Agonists and Evaluation of Physical Properties as Potential Overactive Bladder Therapies: Part 5

Journal of Medicinal Chemistry
2009.0

Abstract

As an extension of research conducted on beta(3)-adrenergic receptor agonists as potential drugs for treating overactive bladder (OAB), novel series containing an acylsulfonamide moiety instead of the carboxylic acid moiety were evaluated. These compounds have been identified as potent and selective human beta(3)-AR agonists with improved oral bioavailability compared to the previous series. Results of structure-activity relationship (SAR) studies and cassette dosing evaluation in dogs showed several analogues (namely, 6h, 6j, 6o, 7e, and 9e) to have an excellent balance of in vitro potency and selectivity, pharmacokinetic (PK) profile, and an in vivo OAB model. Here we examined the relaxation response in dog detrusor muscle strips to a KCl induced tonic concentration. Results showed that the potency of in vitro relaxation response was not mirrored in the potency of the cAMP accumulation in CHO cell lines. Surprisingly, the EC(50) values of 6e and 7e found to induce relaxation of isolated bladder strips were over 50-fold higher than the cAMP accumulation in cell line. In general, increased lipophilicity led to decreased potency for the bladder relaxation compared with cAMP accumulation in CHO cell lines, indicating that lipophilicity is crucial for OAB drug candidates to improve beta(3) activity.

Knowledge Graph

Similar Paper

Discovery of Highly Potent and Selective Biphenylacylsulfonamide-Based β<sub>3</sub>-Adrenergic Receptor Agonists and Evaluation of Physical Properties as Potential Overactive Bladder Therapies: Part 5
Journal of Medicinal Chemistry 2009.0
Discovery of a Novel Series of Biphenyl Benzoic Acid Derivatives as Potent and Selective Human β<sub>3</sub>-Adrenergic Receptor Agonists with Good Oral Bioavailability. Part I
Journal of Medicinal Chemistry 2008.0
Discovery of a Novel Series of Biphenyl Benzoic Acid Derivatives as Highly Potent and Selective Human β3 Adrenergic Receptor Agonists with Good Oral Bioavailability. Part II
Journal of Medicinal Chemistry 2008.0
Synthesis and Evaluation of Potent and Selective β<sub>3</sub> Adrenergic Receptor Agonists Containing Acylsulfonamide, Sulfonylsulfonamide, and Sulfonylurea Carboxylic Acid Isosteres
Journal of Medicinal Chemistry 2002.0
Discovery of highly potent and selective biphenylacylsulfonamide-based β3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the β2-adrenergic receptor: Part 6
Bioorganic &amp; Medicinal Chemistry Letters 2009.0
Discovery of NovelN-Phenylglycine Derivatives as Potent and Selective β<sub>3</sub>-Adrenoceptor Agonists for the Treatment of Frequent Urination and Urinary Incontinence
Journal of Medicinal Chemistry 2001.0
Discovery of Novel Indazole Derivatives as Orally Available β<sub>3</sub>-Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects
Journal of Medicinal Chemistry 2017.0
Discovery of Vibegron: A Potent and Selective β<sub>3</sub>Adrenergic Receptor Agonist for the Treatment of Overactive Bladder
Journal of Medicinal Chemistry 2016.0
Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human β3-adrenergic receptor agonists: Part IV
Bioorganic &amp; Medicinal Chemistry Letters 2008.0
Discovery of a novel, potent and selective human β3-adrenergic receptor agonist
Bioorganic &amp; Medicinal Chemistry Letters 2005.0